AAFP backs FDA tentative trans fats determination

AAFP backs FDA tentative trans fats determination

(HealthDay)—The American Academy of Family Physicians (AAFP) has expressed their support for the U.S. Food and Drug Administration's tentative determination regarding partially hydrogenated oils (PHOs) as food additives.

Noting that PHOs have been used in food for many years based on self-determinations that such use is generally safe, Jeffrey J. Cain, M.D., board chair of the AAFP, responded via letter to the FDA's request for comments about the tentative determination regarding PHOs. If the tentative determination is finalized, food manufacturers will no longer be allowed to sell PHOs unless the manufacturer has received FDA approval.

In a literature review, members of the AAFP's Americans in Motion-Healthy Interventions initiative panel found that PHOs contribute to obesity in children and adults, have adverse effects on , increase the risk of , and contribute to insulin resistance.

"The AAFP reviewed the scientific evidence cited and we are pleased to wholeheartedly support the FDA's determination that PHOs are not generally safe for use in food," Cain writes in the letter.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

AAFP to Obama: Family docs key in violence prevention

Jan 25, 2013

(HealthDay)—Family physicians can play a role in addressing and preventing violence in the community, according to a Jan. 17 letter to President Obama from the American Association of Family Physicians ...

IPAs and PHOs viable option for small independent practices

Aug 09, 2013

(HealthDay)—For small and medium-size independent practices, sharing care management and information technology resources with other practices through an independent practice association (IPA) or physician-hospital ...

FDA encourages opioid prescribers to pursue training

Mar 12, 2013

(HealthDay)—Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according ...

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments